PMID- 24456363
OWN - NLM
STAT- MEDLINE
DCOM- 20140902
LR  - 20220408
IS  - 1557-7600 (Electronic)
IS  - 1096-620X (Print)
IS  - 1096-620X (Linking)
VI  - 17
IP  - 1
DP  - 2014 Jan
TI  - Korean red ginseng improves glucose control in subjects with impaired fasting 
      glucose, impaired glucose tolerance, or newly diagnosed type 2 diabetes mellitus.
PG  - 128-34
LID - 10.1089/jmf.2013.2889 [doi]
AB  - This study was designed to evaluate the effect of Korean red ginseng (KRG) 
      supplementation on glucose control in subjects with impaired fasting glucose 
      (IFG), impaired glucose tolerance (IGT), or newly diagnosed type 2 diabetes 
      mellitus (T2DM). The study was a 12-week randomized, double-blinded, 
      placebo-controlled (5 g of KRG [n=21] or placebo [n=20] in tablet form) trial. 
      Glucose-related biomarkers, including serum and whole blood levels of glucose, 
      insulin, and C-peptide, were measured by 2-h oral glucose tolerance tests (OGTTs) 
      at baseline and after the 12-week intervention. After the intervention, the test 
      group showed a significant decrease in serum levels of glucose at 30 min 
      (-22.24+/-10.77 mg/dL) and whole blood levels of glucose at 30 min 
      (-17.52+/-5.22 mg/dL). In addition, the test group tended to have lower whole blood 
      levels of glucose at 0 min and glucose area under curve (AUC). However, the 
      placebo group did not show any changes in blood glucose-related indices. The 
      changes (difference from baseline) in serum glucose levels at 30 min, whole blood 
      glucose levels at 60 min, and glucose AUC during OGTTs in the test group 
      exhibited a tendency toward a decrease from those in the placebo group. There 
      were significant decreases or trends toward a decrease in both serum insulin and 
      C-peptide concentrations at most time intervals in the test group. In conclusion, 
      KRG supplementation (5 g/day) may be beneficial for controlling serum and whole 
      blood glucose levels compared with placebo among patients with IFG, IGT, or T2DM.
FAU - Bang, Hyangju
AU  - Bang H
AD  - 1 National Leading Research Laboratory for Clinical Nutrigenetics/Nutrigenomics, 
      Department of Food and Nutrition, Yonsei University , Seoul, Republic of Korea.
FAU - Kwak, Jung Hyun
AU  - Kwak JH
FAU - Ahn, Hyeon Yeong
AU  - Ahn HY
FAU - Shin, Dong Yeob
AU  - Shin DY
FAU - Lee, Jong Ho
AU  - Lee JH
LA  - eng
SI  - IRCT/NCT01911663
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Med Food
JT  - Journal of medicinal food
JID - 9812512
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy/metabolism
MH  - Fasting/blood
MH  - Female
MH  - Glucose Intolerance/diagnosis/*drug therapy/metabolism
MH  - Humans
MH  - Insulin/blood
MH  - Male
MH  - Middle Aged
MH  - Plant Extracts/*administration & dosage
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC3901349
EDAT- 2014/01/25 06:00
MHDA- 2014/09/03 06:00
PMCR- 2015/01/01
CRDT- 2014/01/25 06:00
PHST- 2014/01/25 06:00 [entrez]
PHST- 2014/01/25 06:00 [pubmed]
PHST- 2014/09/03 06:00 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - 10.1089/jmf.2013.2889 [pii]
AID - 10.1089/jmf.2013.2889 [doi]
PST - ppublish
SO  - J Med Food. 2014 Jan;17(1):128-34. doi: 10.1089/jmf.2013.2889.